A live varicella vaccine used for children in hospitals.
A live varicella vaccine was developed and the following results obtained: 1. The vaccine was safely and effectively used for children in hospital with various underlying diseases; some of the children had been receiving immunosuppressive therapy. 2. Spread of varicella could be prevented by immediate inoculation of the vaccine in hospital or at home when vaccine was given to susceptible children within 72 hours after exposure. 3. Persistence of neutralizing antibody and prevention of natural varicella have been confirmed in a two-year follow-up study of the vaccine recipients. 4. No contact infection from vaccine recipients to susceptible children in closed institutions was detected (Asano et al., 1976). 5. Varicella skin antigen was prepared and was found useful for clinical purposes, e.g., by providing a convenient means of determining the susceptibility of individuals to clinical varicella.
D000914:Antibodies, Viral / Q000096:biosynthesis; D000956:Antigens, Viral / Q000008:administration & dosage; D002644:Chickenpox / Q000175:diagnosis / Q000517:prevention & control*; D002648:Child; D014645:Herpesvirus 3, Human / Q000276:immunology*; D006761:Hospitals; D006801:Humans; D007938:Leukemia / Q000628:therapy; D012882:Skin Tests; D013997:Time Factors; D014765:Viral Vaccines / Q000627:therapeutic use*
D000914:Antibodies, Viral; D000956:Antigens, Viral; D014765:Viral Vaccines